Novartis CEO says Trump’s drug pricing plan creates a very difficult situation for makers and patients
Novartis chief executive Vas Narasimhan warned that the United States drug‑pricing policy under President Trump presents a "very difficult situation" for both drugmakers and patients.
He said the reality of the policy will soon catch up with the industry, implying that current pricing pressures could intensify and affect access to medicines.
The column also noted other industry news, including Purdue Pharma's sentencing and Boehringer Ingelheim reporting trial results for an obesity drug aimed at preserving muscle mass.
These items highlight ongoing challenges and developments that could shape the pharmaceutical landscape in the coming months.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that